IMPERIAL BIOSCIENCE LTD SHORTLISTED FOR THE BARCLAYS ENTREPRENEUR AWARDS 2023
London, Aug 2023
Imperial Bioscience Ltd is thrilled to announce its shortlisting as a finalist for the prestigious Barclays Entrepreneur Awards 2023. This recognition comes in the highly coveted Eagle Labs Innovation Award, sponsored by the Eagle Labs category, and celebrates Imperial Bioscience's commitment to driving innovation and revolutionising drug delivery through its cutting-edge Microarray Patch (MAP) technology.
The Barclays Entrepreneur Awards are renowned for honouring outstanding entrepreneurs and high-growth businesses that contribute significantly to their industries, the economy, and society through original and positive initiatives. Imperial Bioscience's selection as a finalist highlights its unwavering dedication to transforming the pharmaceutical landscape and enhancing patient-centric solutions.
"We are immensely proud to be named a finalist for the Barclays Entrepreneur Awards 2023," said Dr Muhammet Avcil, CEO of Imperial Bioscience Ltd. "This prestigious recognition underscores the relentless efforts of our exceptional team, who continually push the boundaries of innovation in the pharmaceutical industry. Our Microarray Patch technology has the potential to revolutionise drug delivery, empowering patients and improving outcomes globally. This nomination is a testament to our commitment to advancing healthcare through cutting-edge solutions."
The Barclays Entrepreneur Awards serve as a platform to celebrate innovative business ideas and acknowledge the achievements of home-grown ventures in the UK. Imperial Bioscience's shortlisting is a testament to its continuous growth, innovative approaches, and positive impact on the pharmaceutical sector.
The winners of the Barclays Entrepreneur Awards 2023 will be announced at a grand ceremony on Wednesday, 29 November 2023, at a central London location. The event will bring together industry leaders, entrepreneurs, and businesses from various sectors to celebrate innovation, excellence, and success.
About Imperial Bioscience Ltd:
Imperial Bioscience Ltd is a biopharmaceutical company committed to revolutionising drug delivery through its innovative Microarray Patch (MAP) technology. With a relentless focus on innovation, patient-centric solutions, and cutting-edge research, Imperial Bioscience is at the forefront of advancements in the pharmaceutical industry.
For more information, please visit www.imperialbioscience.co.uk.